Blog
RSS FeedPosted by Michael Wonder on 12 Jul 2021
Teplizumab awarded Innovation Passport in the United Kingdom for the delay of onset of clinical type 1 diabetes in at risk individuals
12 July 2021 - Designation is the first step in a new MHRA initiative to accelerate the development and access to ...
Posted by Michael Wonder on 12 Jul 2021
FDA approves daratumumab and hyaluronidase-fihj with pomalidomide and dexamethasone for multiple myeloma
12 July 2021 - On 9 July 2021, the FDA approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech) in combination ...
Posted by Michael Wonder on 12 Jul 2021
Minister for Health announces HSE approval to reimburse patisiran (Onpattro)
12 July 2021 - The Minister for Health, Stephen Donnelly TD is pleased to announce that the drug patisiran (Onpattro) ...
Posted by Michael Wonder on 12 Jul 2021
FDA’s expansive Alzheimer’s drug approval surprised even top agency officials
9 July 2021 - The FDA’s contentious decision to approve a new Alzheimer’s drug for every single patient with the ...
Posted by Michael Wonder on 12 Jul 2021
‘MSD Korea proposed unprecedented offer for Keytruda reimbursement’
12 July 2021 - MSD’s Keytruda (pembrolizumab), immunotherapy for lung cancer, is the company’s flagship item that sold $14.38 billion ...
Posted by Michael Wonder on 12 Jul 2021
Drug prices weigh on older Americans
9 July 2021 - Most Americans ages 50 and older rely on prescription drugs for their health, yet many worry ...
Posted by Michael Wonder on 12 Jul 2021
Wesfarmers lobs $687 million takeover of Australian Pharmaceutical Industries
12 July 2021 - Wesfarmers has lobbed a $687 million takeover of Priceline owner API. But don’t expect pharmacies to pop ...
Posted by Michael Wonder on 11 Jul 2021
What a waste! The National Academy of Medicine’s report on oversized vials of expensive drugs
9 July 2021 - In 2016, my colleagues and I tabulated $2 billion in excess spending across the US health care ...
Posted by Michael Wonder on 11 Jul 2021
The growing problem of out of pocket costs and affordability in employer sponsored insurance
9 July 2021 - While policy makers and health leaders have appropriately focused on addressing the COVID-19 pandemic, underlying racial and ...
Posted by Michael Wonder on 11 Jul 2021
UK’s MHRA accepts Humanigen’s submission of lenzilumab for marketing authorisation in COVID-19 for expedited rolling review
9 July 2021 - Humanigen today announced its submission for Marketing Authorization for lenzilumab in COVID-19, begun in June 2021, has ...
Posted by Michael Wonder on 11 Jul 2021
Drug prices are one focus of Biden’s push to boost competition
9 July 2021 - Executive order calls for easing access for generics, Canadian drugs to lower costs. ...
Posted by Michael Wonder on 10 Jul 2021
FDA seeks to probe talks between staff and Biogen on Alzheimer’s drug
9 July 2021 - The FDA’s chief is taking the highly unusual step of asking for a federal investigation of doctors ...
Posted by Michael Wonder on 10 Jul 2021
Frustrated cystic fibrosis patients await PBS subsidy to 'life changing' drug
9 July 2021 - In the days after Queensland mother Ella Sawyer gave birth, her baby daughter Evie didn't gain ...
Posted by Michael Wonder on 10 Jul 2021
Bayer’s Kerendia (finerenone) receives U.S. FDA approval for treatment of patients with chronic kidney disease associated with type 2 diabetes
9 July 2021 - First and only non-steroidal mineralocorticoid receptor antagonist approved for adults with chronic kidney disease associated with type ...
Posted by Michael Wonder on 10 Jul 2021
Application for cystic fibrosis medicine received by PHARMAC
9 July 2021 - PHARMAC is starting its funding assessment process for a new cystic fibrosis medication after receiving an ...